https://biotechmorning.com/news/stealth-antibody-vir-astellas-prostate-cancer-deal Biotech Morning en 2026-06-29T14:27:45.289Z The Stealth Antibody That Fooled Its Way Into a $1.7B Prostate Cancer Deal https://biotechmorning.com/news/novo-nordisk-cagrisema-loses-to-zepbound-3 Biotech Morning en 2026-06-29T14:26:53.981Z Novo Nordisk Just Lost the Obesity Drug Super Bowl https://biotechmorning.com/news/adhd-drug-centanafadine-anxiety-otsuka-phase-3b Biotech Morning en 2026-06-29T14:26:01.104Z The ADHD Drug That Might Actually Help Your Anxiety Too https://biotechmorning.com/news/astrazeneca-strensiq-successor-mixed-phase-3-results Biotech Morning en 2026-06-29T14:25:02.913Z AstraZeneca's Strensiq Sequel Aced the Kids' Test. Then Came the Adults. https://biotechmorning.com/news/novartis-qeq278-zero-responses-30-patients Biotech Morning en 2026-06-29T14:24:00.305Z Novartis Tested a Cancer Drug on 30 Patients. None of Them Responded. https://biotechmorning.com/news/lilly-zepbound-vial-pricing-glp1-price-war Biotech Morning en 2026-06-29T14:23:11.486Z Lilly's Quiet Move to Win the GLP-1 Price War https://biotechmorning.com/news/sarepta-black-box-warning-layoffs-elevidys Biotech Morning en 2026-06-29T14:22:08.447Z Sarepta's Worst Week: A Black Box Warning and 500 Pink Slips https://biotechmorning.com/news/ipsen-kartos-myelofibrosis-deal Biotech Morning en 2026-06-29T14:21:16.154Z Ipsen Just Bet $1.75 Billion on a Drug That Doesn't Have Data Yet https://biotechmorning.com/news/alumis-250m-ipo-back-to-back-raises Biotech Morning en 2026-06-28T14:24:47.990Z Alumis Just Raised $250M Going Public. Three Months Ago, It Raised $259M. https://biotechmorning.com/news/immunovant-39m-batoclimab-termination Biotech Morning en 2026-06-28T14:23:56.299Z Immunovant Just Paid $39M to Walk Away From a Drug That Didn't Work https://biotechmorning.com/news/cipepofol-china-anesthetic-fda-approval Biotech Morning en 2026-06-28T14:23:13.681Z The Anesthetic That Crossed the Pacific and Made FDA History https://biotechmorning.com/news/incyte-120m-genesis-ai-drug-discovery-bet Biotech Morning en 2026-06-28T14:22:14.132Z Incyte Just Bet $120M That AI Can Build Its Next Drug Pipeline https://biotechmorning.com/news/liminatus-innocsai-320m-all-stock-deal Biotech Morning en 2026-06-28T14:21:19.777Z A Biotech Worth $5 Million Just Bought a Company for $320 Million https://biotechmorning.com/news/annexon-huntington-patient-dropouts-stock-crash Biotech Morning en 2026-06-28T14:20:26.242Z Five Patients Quit and Annexon Lost a Third of Its Value https://biotechmorning.com/news/lilly-202m-engage-dna-delivery-acquisition Biotech Morning en 2026-06-28T14:19:30.200Z Lilly Just Paid $202M for a Company With Zero Drugs https://biotechmorning.com/news/biogen-apellis-pipeline-gutted Biotech Morning en 2026-06-28T14:18:35.407Z Biogen Spent $5.6B on Apellis. Then It Torched the Science. https://biotechmorning.com/news/infex-therapeutics-resp-x-phase-2a-ncfb-insmed Biotech Morning en 2026-06-28T14:17:34.037Z The Tiny UK Biotech Trying to Out-Insmed Insmed